Cargando…

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denaro, Nerina, Garrone, Ornella, Occelli, Marcella, Fea, Elena, Granetto, Cristina, Merlano, Marco Carlo, Numico, Gianmauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SMC Media Srl 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276930/ https://www.ncbi.nlm.nih.gov/pubmed/34268267 http://dx.doi.org/10.12890/2021_002639

Ejemplares similares

Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion
por: Numico, Gianmauro, et al.
Publicado: (2016)

Heterogeneity of colon cancer: from bench to bedside
por: Merlano, Marco C, et al.
Publicado: (2017)

Immune-related response criteria: light and shadows
por: Merlano, Marco, et al.
Publicado: (2016)

How I treat squamous ENT cancer
por: Merlano, Marco Carlo, et al.
Publicado: (2019)

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
por: Merlano, Marco Carlo, et al.
Publicado: (2022)

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
por: Abbona, Andrea, et al.
Publicado: (2023)

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
por: Merlano, Marco Carlo, et al.
Publicado: (2021)

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
por: Paccagnella, Matteo, et al.
Publicado: (2022)

Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment
por: Merlano, Marco Carlo, et al.
Publicado: (2023)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations
por: Denaro, Nerina, et al.
Publicado: (2013)

Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience
por: Denaro, Nerina, et al.
Publicado: (2016)

Long noncoding RNAs as regulators of cancer immunity
por: Denaro, Nerina, et al.
Publicado: (2018)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Head and neck cancer: improving outcomes with a multidisciplinary approach
por: Lo Nigro, Cristiana, et al.
Publicado: (2017)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019)

Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC)
por: Denaro, Nerina, et al.
Publicado: (2020)

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody
por: Shiba, Michiru, et al.
Publicado: (2018)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
por: Azuma, Takeshi, et al.
Publicado: (2021)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jr09crm0ot5qvkje7gubqlc1p8